A Randomized, Placebo-Controlled, Blinded Clinical Trial Evaluating PCSO-524 as an Adjunctive Therapy for Noninfectious Pododermatitis in Rabbits
2
Issued Date
2025-01-01
Resource Type
ISSN
20908113
eISSN
20420048
Scopus ID
2-s2.0-105024852641
Journal Title
Veterinary Medicine International
Volume
2025
Issue
1
Rights Holder(s)
SCOPUS
Bibliographic Citation
Veterinary Medicine International Vol.2025 No.1 (2025)
Suggested Citation
Sakcamduang W., Siriarchawattana N., Korjaranjit P., Natepoo V., Suriyakhun N., Yinharnmingmongkol C., Taechikantaphat M. A Randomized, Placebo-Controlled, Blinded Clinical Trial Evaluating PCSO-524 as an Adjunctive Therapy for Noninfectious Pododermatitis in Rabbits. Veterinary Medicine International Vol.2025 No.1 (2025). doi:10.1155/vmi/4177859 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/113636
Title
A Randomized, Placebo-Controlled, Blinded Clinical Trial Evaluating PCSO-524 as an Adjunctive Therapy for Noninfectious Pododermatitis in Rabbits
Author's Affiliation
Corresponding Author(s)
Other Contributor(s)
Abstract
This study evaluated the efficacy and safety of PCSO-524, a natural supplement containing omega-3 fatty acids, as an adjunctive therapy for noninfectious pododermatitis (Grades 1-2) in rabbits. In a randomized, placebo-controlled, blinded trial, 23 rabbits with noninfectious pododermatitis received either PCSO-524 or a placebo along with standard treatments for 56 days. PCSO-524 supplementation led to a statistically significant reduction in the mean lesion size of both hind limbs within the PCSO group compared to baseline (Day 0: 98.55 ± 52.75 mm<sup>2</sup>, Day 56: 53.18 ± 21.54 mm<sup>2</sup>; p = 0.002), while the placebo group did not show significant changes (Day 0: 93.98 ± 43.88 mm<sup>2</sup>, Day 56: 75.61 ± 115.68 mm<sup>2</sup>; p = 0.58). Both groups exhibited alterations in white blood cell populations (increased monocytes, decreased eosinophils) within normal ranges, and a consistently elevated heterophil-to-lymphocyte ratio (HLR; > 1:1). No adverse events were associated with PCSO-524. This study provides initial evidence for the safety and potential efficacy of a natural supplement containing omega-3 fatty acids as an adjunctive therapy for noninfectious pododermatitis in rabbits.